Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of LY3015014 in primary hypercholesterolemia
NL-OMON38601Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of frovocimab in hypercholesterolemia (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean percentage change in LDL-C from baseline to week 16. Started Aug 2013; status: active, not recruiting.
02
Drugs
frovocimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON38601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38601.